810 Preliminary safety, tolerability and efficacy results of KN026 in combination with KN046 in patients with HER2 aberrated solid tumors

810 Preliminary safety, tolerability and efficacy results of KN026 in combination with KN046 in patients with HER2 aberrated solid tumors

Bibliographic Details
Main Authors: Dan Liu, Jing Yang, Lin Shen, Yue Yang, Ting Xu, Jifang Gong, Zhi Dong, June Xu, Yakun Qi, Jie Men, Paul Kong
Format: Article
Language:English
Published: BMJ Publishing Group 2020-11-01
Series:Journal for ImmunoTherapy of Cancer
id doaj-00623983293a4f6b8c5349d69879b125
record_format Article
spelling doaj-00623983293a4f6b8c5349d69879b1252020-12-11T10:04:07ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262020-11-018Suppl 310.1136/jitc-2020-SITC2020.0810810 Preliminary safety, tolerability and efficacy results of KN026 in combination with KN046 in patients with HER2 aberrated solid tumorsDan Liu0Jing Yang1Lin Shen2Yue Yang3Ting Xu4Jifang Gong5Zhi Dong6June Xu7Yakun Qi8Jie Men9Paul Kong101Beijing Cancer Hospital, Beijing, China2Jiangsu Alphamab Biopharmaceuticals Co., suzhou, ChinaDepartment of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China2Jiangsu Alphamab Biopharmaceuticals Co., suzhou, China2Jiangsu Alphamab Biopharmaceuticals Co., suzhou, ChinaDepartment of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China1Beijing Cancer Hospital, Beijing, China2Jiangsu Alphamab Biopharmaceuticals Co., suzhou, China2Jiangsu Alphamab Biopharmaceuticals Co., suzhou, China2Jiangsu Alphamab Biopharmaceuticals Co., suzhou, China2Jiangsu Alphamab Biopharmaceuticals Co., suzhou, China
collection DOAJ
language English
format Article
sources DOAJ
author Dan Liu
Jing Yang
Lin Shen
Yue Yang
Ting Xu
Jifang Gong
Zhi Dong
June Xu
Yakun Qi
Jie Men
Paul Kong
spellingShingle Dan Liu
Jing Yang
Lin Shen
Yue Yang
Ting Xu
Jifang Gong
Zhi Dong
June Xu
Yakun Qi
Jie Men
Paul Kong
810 Preliminary safety, tolerability and efficacy results of KN026 in combination with KN046 in patients with HER2 aberrated solid tumors
Journal for ImmunoTherapy of Cancer
author_facet Dan Liu
Jing Yang
Lin Shen
Yue Yang
Ting Xu
Jifang Gong
Zhi Dong
June Xu
Yakun Qi
Jie Men
Paul Kong
author_sort Dan Liu
title 810 Preliminary safety, tolerability and efficacy results of KN026 in combination with KN046 in patients with HER2 aberrated solid tumors
title_short 810 Preliminary safety, tolerability and efficacy results of KN026 in combination with KN046 in patients with HER2 aberrated solid tumors
title_full 810 Preliminary safety, tolerability and efficacy results of KN026 in combination with KN046 in patients with HER2 aberrated solid tumors
title_fullStr 810 Preliminary safety, tolerability and efficacy results of KN026 in combination with KN046 in patients with HER2 aberrated solid tumors
title_full_unstemmed 810 Preliminary safety, tolerability and efficacy results of KN026 in combination with KN046 in patients with HER2 aberrated solid tumors
title_sort 810 preliminary safety, tolerability and efficacy results of kn026 in combination with kn046 in patients with her2 aberrated solid tumors
publisher BMJ Publishing Group
series Journal for ImmunoTherapy of Cancer
issn 2051-1426
publishDate 2020-11-01
work_keys_str_mv AT danliu 810preliminarysafetytolerabilityandefficacyresultsofkn026incombinationwithkn046inpatientswithher2aberratedsolidtumors
AT jingyang 810preliminarysafetytolerabilityandefficacyresultsofkn026incombinationwithkn046inpatientswithher2aberratedsolidtumors
AT linshen 810preliminarysafetytolerabilityandefficacyresultsofkn026incombinationwithkn046inpatientswithher2aberratedsolidtumors
AT yueyang 810preliminarysafetytolerabilityandefficacyresultsofkn026incombinationwithkn046inpatientswithher2aberratedsolidtumors
AT tingxu 810preliminarysafetytolerabilityandefficacyresultsofkn026incombinationwithkn046inpatientswithher2aberratedsolidtumors
AT jifanggong 810preliminarysafetytolerabilityandefficacyresultsofkn026incombinationwithkn046inpatientswithher2aberratedsolidtumors
AT zhidong 810preliminarysafetytolerabilityandefficacyresultsofkn026incombinationwithkn046inpatientswithher2aberratedsolidtumors
AT junexu 810preliminarysafetytolerabilityandefficacyresultsofkn026incombinationwithkn046inpatientswithher2aberratedsolidtumors
AT yakunqi 810preliminarysafetytolerabilityandefficacyresultsofkn026incombinationwithkn046inpatientswithher2aberratedsolidtumors
AT jiemen 810preliminarysafetytolerabilityandefficacyresultsofkn026incombinationwithkn046inpatientswithher2aberratedsolidtumors
AT paulkong 810preliminarysafetytolerabilityandefficacyresultsofkn026incombinationwithkn046inpatientswithher2aberratedsolidtumors
_version_ 1724386412540723200

Similar Items